Results from the comparison of AMD treatments trials, in which patients were treated for 2 years with anti–vascular endothelial growth factor (VEGF) agents, showed that the 2-year incidence of geographic atrophy (GA) was approximately 18%.1 When GA was present at the fovea, the visual acuity was markedly decreased.2,3 Grunwald et al2 described a number of risk factors associated with faster GA growth in patients with AMD treated with anti-VEGF medications for a period of 2 years. The gene discussed is VEGFA; the disease is age-related macular degeneration.